BiQ: Weekly Recap for February 16, 2025 (Free)

Welcome to the BiQ Weekly Recap #4!

First, I'd like to welcome all the new Biotech iQ members who joined over these past few weeks--thank you for joining the BiQ Community. I've been a biotech investor for over two decades, but BiQ is a new service, and I'm humbled and grateful for its warm reception from the biotech community.

BiQ is 100% subscriber supported. I am not beholden to any outside interests, don't write for any other publications, and this service doesn't derive any revenue from any source other than member subscriptions. I also do not need to "dress up" my short-term performance for sites like TipRanks, or publish a required number of articles for sites like Seeking Alpha. This allows me to provide my subscribers with the best service and unbiased information I can--and maintain my focus on long-term value creation rather than short-term "window dressing". None of this would be possible without your support.

If you haven't already done so, I encourage members to join the BiQ Community Chat Server on Discord. Free members have access to the Public channels, while Premium members have access to the Public and Premium channels. BiQ Community Chat is the quickest way to receive updates from BiQ in real-time. It's also a great place to discuss biotech/medtech investing ideas, ask questions, and connect with other biotech/medtech enthusiasts.

Click here for instructions on how to access the BiQ Community Chat Server.

It was another relatively flat week for the XBI, but with plenty of volatility along the way. The index opened Monday trading at 91.84 and closed Friday at 91.39, hitting a low of 87.90 on Wednesday morning but mostly recovering through Friday's close--with heavy volume coming in during the last few minutes of trading.

Fortunately, the BiQ Active Portfolio performed somewhat better, as we can see from the weekly performance chart below, with 14/20 BiQ tickers closing green for the week.

BiQ Service Updates

• Fixed a bug that was causing the site's main menu bar to display incorrectly under some circumstances.

BiQ Coverage List Updates

• Posted an updated iQ Cheat Sheet for SWTX.
• Updated NMT Outlook and Rating for SWTX.
• Updated iQ Cheat Sheet for RCEL after Q4 earnings.
• Removed TERN from the Watch List.
• Added ALLO to the Watch List.
• Added APLT to the Watch List.

BiQ Trades

Please consider becoming a BiQ Premium Member to view BiQ real-time trades.

BiQ News & Updates

• The big news this past week was confirmation that Merck KGaA is in active negotiations to purchase SWTX. There's no way to predict if a buyout will happen. I recommend caution for members thinking of trading in anticipation of a buyout. I see SWTX shares as overpriced based on fundamentals. While shares could have significant upside if a buyout happens, they could also pull back significantly from current levels if it fails to materialize. Please read the update published earlier this week by clicking here.
• In other big news, SWTX received FDA approval for Mirdametinib for treating adult and pediatric NF1-PN. This is a significant milestone for SWTX and dramatically expands the company's TAM to now include two potentially blockbuster indications. The approval was noted in the updated iQ Cheat Sheet, which can be accessed here. Please read the article published earlier this week by clicking here.
• RCEL reported official Q4 earnings. You can read the update posted earlier this week by clicking here.
• Added new events for PROF and RCEL to the Events Calendar.

BiQ Past & Current Performance Update

Please visit the Coverage List & Cheat Sheets page to see the complete BiQ Coverage List and access iQ Cheat Sheets for all companies under Active Coverage.

BiQ Social Media Highlights

Biotech iQ is 100% subscriber supported. If you find this information helpful, please spread the word. You can also follow me on X @ Biotech iQ (_Biotech_iQ).

Biotech iQ is not an investment professional, and nothing on this page or this website should be considered investment advice. Please consult with a licensed investment professional as necessary.